pageBanner

Aerpio Therapeutics, Inc.

aero

CEO: Joseph Gardner

Headquarters: Cincinnati, Ohio

URL: www.aerpio.com

Investment Date: March 2017

Initial Funding: $40,000,000

Trading Venue: Pending

Aerpio Therapeutics: Is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The lead programs include a Tie2 activator for diabetic retinopathy (DR) and a hypoxia-inducible factor α (HIF-α) stabilizer for the treatment of inflammatory bowel disease. The lead compound for the Tie2 program, AKB-9778, recently completed a proof-of-concept, Phase 2a study (TIME-2). AKB-4924, the lead compound in our HIF-α stabilization program, has recently completed a Phase 1a study.

Investors:

aero4

aero2

DISCLAIMER

This website and the information herein is proprietary and confidential and is being presented by Montrose Capital Partners and its affiliates and subsidiaries (“Montrose”) to provide an overview of the Montrose business operations, capabilities and related products/services. You agree to treat this information, including information about possible future transactions, transaction structures and their terms, in strict confidence, not to disclose such information to any other party and not to use such information for any purpose other than in evaluating an interest, if any, in the proposed transactions.

This website was prepared by Montrose for illustration and informational purposes only, and should not be construed as a solicitation to effect, attempt to effect, either transactions in securities or the rendering of personalized investment advice. This website is not to be construed as a recommendation or an offer to sell or a solicitation of an offer to buy securities. Any opinions or comments expressed herein are not necessarily representative of the opinions and views of Montrose or its management, employees, agents or other representatives. Any views, opinions and advice provided in this website has been prepared without taking into account the investment objectives, financial objectives, situation or specific needs of any individual person. Certain information in this website has been derived from publicly available sources that we believe to be accurate; however, we have not verified such information and no rewebsite or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information or opinions and conclusions, if any, in this website. No rewebsite is being made that any investment undertaken, will or is likely to achieve profits or avoid substantial losses. There is a risk of substantial loss in all transactions. To the maximum extent permitted by law, neither Montrose or its management, employees, agents or any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this website.

Any dissemination, distribution or reproduction of this website is strictly prohibited without the consent of Montrose. No part of this website may be reproduced, stored, or transmitted by any means without the express written consent of Montrose. All brands, company names, and product names are trademarks or registered trademarks of their respective holder.

© 2017 Montrose Partners. All rights reserved.

Agree